Conclusion: Simultaneous neutralization of IL-1β and IL-18 may represent an efficacious therapeutic approach in sJIA patients with chronic/relapsing MAS with liver and marrow involvement. This evidence concerns the gene IL1B and macrophage activation syndrome.